Tarsus: TP-03 Phase 2a Clinical Trial Shows Positive Data In MGD In Patients With Demodex Mites
Tarsus Pharmaceuticals, Inc. (TARS) announced Monday positive topline results from the Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.
Source: rttnews.com